J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 8, Number 2, February 2016, pages 97-104

Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure

Figure 3. Medications at discharge. ARB: angiotensin receptor blocker; ACE-I: angiotensin converting enzyme inhibitor.

Figure 5. Medications in patients with HFrEF, borderline and HFpEF according to LVEF. HFrEF: heart failure with reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; ARB: angiotensin receptor blocker; ACE-I: angiotensin converting enzyme inhibitor; CCB: calcium-channel blocker.

**Table 1.** Patient Characteristics at Admission
	Group 2013 (n = 158)
NYHA: New York Heart Association; HTN: hypertension; DM: diabetes mellitus; DL: dyslipidemia; CKD: chronic kidney disease; PMI: pacemaker implantation; ICD: implantable cardioverter defibrillator; CRT: cardiac resynchronization therapy; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; BNP: brain natriuretic peptide; NT-proBNP: amino-terminal pro-BNP; Cr: creatinine; eGFR: estimated glomerular filtration rate; CCr: creatinine clearance; UA: uric acid; Na: sodium; K: potassium; Hb: hemoglobin; CRP: C-reactive protein; TC: total cholesterol; TG: triglyceride; HDL-c: high-density lipoprotein-cholesterol; LDL-c: low-density lipoprotein-cholesterol; LAd: left atrial dimension; LVEDd: left ventricular end diastolic dimension; LVEF: left ventricular ejection fraction.
Male, n (%)	86 (54)
Age	74 ± 13
Height, m	1.58 ± 0.10
Weight, kg	59.2 ± 14.4
NYHA classification	3.5 ± 0.7
Hospitalized days, days	21 ± 13
HTN, n (%)	94 (59)
DM, n (%)	53 (34)
DL, n (%)	80 (51)
CKD, n (%)	118 (75)
Anemia, n (%)	117 (74)
Smoking, current, n (%)	21 (13)
Smoking, former, n (%)	36 (23)
PM, n (%)	16 (10)
ICD, n (%)	18 (11)
CRT, n (%)	6 (4)
SBP, mm Hg	137 ± 31
DBP, mm Hg	78 ± 18
HR, /min	86 ± 24
Biochemical parameters
BNP, pg/mL	824 ± 702
NT-proBNP, pg/mL	7,569 ± 8,993
Cr, mg/dL	1.3 ± 0.7
eGFR, mL/min/1.73 m²	45 ± 21
CCr, mL/min	47 ± 31
UA, mg/dL	6.9 ± 2.2
Na, mEq/L	140 ± 4
K, mEq/L	4.2 ± 0.6
Hb, g/dL	11.4 ± 2.4
CRP, mg/dL	2.41 ± 4.57
TC, mg/dL	150 ± 38
TG, mg/dL	86 ± 35
HDL-C, mg/dL	39 ± 12
LDL-C, mg/dL	89 ± 30
Echocardiographic parameters
LAd, mm	47.0 ± 8.9
LVEDd, mm	52.5 ± 10.5
LVEF, %	44.7 ± 17.4

Table 1. Patient Characteristics at Admission

Group 2013 (n = 158)

NYHA: New York Heart Association; HTN: hypertension; DM: diabetes mellitus; DL: dyslipidemia; CKD: chronic kidney disease; PMI: pacemaker implantation; ICD: implantable cardioverter defibrillator; CRT: cardiac resynchronization therapy; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; BNP: brain natriuretic peptide; NT-proBNP: amino-terminal pro-BNP; Cr: creatinine; eGFR: estimated glomerular filtration rate; CCr: creatinine clearance; UA: uric acid; Na: sodium; K: potassium; Hb: hemoglobin; CRP: C-reactive protein; TC: total cholesterol; TG: triglyceride; HDL-c: high-density lipoprotein-cholesterol; LDL-c: low-density lipoprotein-cholesterol; LAd: left atrial dimension; LVEDd: left ventricular end diastolic dimension; LVEF: left ventricular ejection fraction.

Male, n (%)

86 (54)

Age

74 ± 13

Height, m

1.58 ± 0.10

Weight, kg

59.2 ± 14.4

NYHA classification

3.5 ± 0.7

Hospitalized days, days

21 ± 13

HTN, n (%)

94 (59)

DM, n (%)

53 (34)

DL, n (%)

80 (51)

CKD, n (%)

118 (75)

Anemia, n (%)

117 (74)

Smoking, current, n (%)

21 (13)

Smoking, former, n (%)

36 (23)

PM, n (%)

16 (10)

ICD, n (%)

18 (11)

CRT, n (%)

6 (4)

SBP, mm Hg

137 ± 31

DBP, mm Hg

78 ± 18

HR, /min

86 ± 24

Biochemical parameters

BNP, pg/mL

824 ± 702

NT-proBNP, pg/mL

7,569 ± 8,993

Cr, mg/dL

1.3 ± 0.7

eGFR, mL/min/1.73 m²

45 ± 21

CCr, mL/min

47 ± 31

UA, mg/dL

6.9 ± 2.2

Na, mEq/L

140 ± 4

K, mEq/L

4.2 ± 0.6

Hb, g/dL

11.4 ± 2.4

CRP, mg/dL

2.41 ± 4.57

TC, mg/dL

150 ± 38

TG, mg/dL

86 ± 35

HDL-C, mg/dL

39 ± 12

LDL-C, mg/dL

89 ± 30

Echocardiographic parameters

LAd, mm

47.0 ± 8.9

LVEDd, mm

52.5 ± 10.5

LVEF, %

44.7 ± 17.4

**Table 2.** Major Courses of HF
HF: heart failure; DCM: dilated cardiomyopathy; HCM: hypertrophic cardiomyopathy; D-HCM: dilated phase of HCM; ARVC: arrhythmogenic right ventricular cardiomyopathy; IHD: ischemic heart disease; HTCM: hypertensive cardiomyopathy; PH: pulmonary hypertension.
DCM, n (%)	16 (10)
HCM, n (%)	4 (3)
D-HCM, n (%)	1 (1)
ARVC, n (%)	1 (1)
Congenital, n (%)	1 (1)
IHD, n (%)	47 (30)
HTCM, n (%)	32 (20)
Valvular heart disease, n (%)	35 (22)
Arrhythmia, n (%)	5 (3)
PH, n (%)	1 (1)
Sarcoidosis, n (%)	1 (1)
Peripartum cardiomyopathy, n (%)	1 (1)
Myocarditis, n (%)	1 (1)
Unknown, n (%)	12 (8)

Table 2. Major Courses of HF

HF: heart failure; DCM: dilated cardiomyopathy; HCM: hypertrophic cardiomyopathy; D-HCM: dilated phase of HCM; ARVC: arrhythmogenic right ventricular cardiomyopathy; IHD: ischemic heart disease; HTCM: hypertensive cardiomyopathy; PH: pulmonary hypertension.

DCM, n (%)

16 (10)

HCM, n (%)

4 (3)

D-HCM, n (%)

1 (1)

ARVC, n (%)

1 (1)

Congenital, n (%)

1 (1)

IHD, n (%)

47 (30)

HTCM, n (%)

32 (20)

Valvular heart disease, n (%)

35 (22)

Arrhythmia, n (%)

5 (3)

PH, n (%)

1 (1)

Sarcoidosis, n (%)

1 (1)

Peripartum cardiomyopathy, n (%)

1 (1)

Myocarditis, n (%)

1 (1)

Unknown, n (%)

12 (8)